Patents by Inventor Kevin X. Chen

Kevin X. Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVE
    Publication number: 20220135558
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 24, 2021
    Publication date: May 5, 2022
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20220127265
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • Fused ring derivative as Areceptor inhibitor
    Patent number: 11312715
    Abstract: Disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and an application of the compound or slat in preparation of drugs for treating diseases related to an A2A receptor.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: April 26, 2022
    Assignees: CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD., CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD., CSTONE PHARMACEUTICALS
    Inventors: Kevin X Chen, Kai Zhou, Boyu Hu, Minliang Xiao, Shuhui Chen
  • Therapeutic compounds and uses thereof
    Patent number: 11247989
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: February 15, 2022
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof
    Patent number: 11174270
    Abstract: A crystal form A of a 3,4-dihydrothieno[3,2-d]pyrimidine compound (1), a preparation method therefor and an application thereof in the preparation of an anti-human cytomegalovirus (HCMV) drug.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: November 16, 2021
    Assignee: Phaeno Therapeutics Co., Ltd.
    Inventors: Jian Xiong, Jingjing Wang, Boyu Hu, Haizhong Tan, Kevin X. Chen, Jian Li, Shuhui Chen
  • PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF
    Publication number: 20210323979
    Abstract: The present invention relates to a group of pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 8, 2019
    Publication date: October 21, 2021
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X CHEN, Fen JIANG, Xinde CHEN, Li ZHANG, Zhaoguo CHEN, Yanxin YU, Kai ZHOU, Boyu HU, Cheng XIE, Shuhui CHEN
  • Anti-influenza virus pyrimidine derivative
    Patent number: 11136319
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: October 5, 2021
    Assignee: Guangdong Raynovent Biotech Co., Ltd.
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Biheteroaryl compounds and uses thereof
    Patent number: 11129832
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: September 28, 2021
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph P. Lyssikatos, Alan G. Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • [1,2,4]triazolo[1,5-c]pyrimidine derivative as Areceptor inhibitor
    Patent number: 11117899
    Abstract: Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to A2A receptor. The R1, R2, R3, ring A, ring B, n, and m are as defined in the specification.
    Type: Grant
    Filed: April 8, 2018
    Date of Patent: September 14, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Yanxin Yu, Xinde Chen, Li Zhang, Zhaoguo Chen, Cheng Xie, Xiaofei Wang, Linghui Wu, Guoping Hu, Jian Li, Shuhui Chen
  • IMIDAXOPYROLONE COMPOUND AND APPLICATION THEREOF
    Publication number: 20210230164
    Abstract: Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 12, 2019
    Publication date: July 29, 2021
    Inventors: Kevin X CHEN, Xiaobing YAN, Jianglei HUANG, Yuekun NIE, Guoping HU, Jian LI, Shuhui CHEN, Jiaqiang DONG, Tie-Lin WANG
  • [1,2,4]triazolo[1,5-c]pyrimidine derivative as Areceptor inhibitor
    Patent number: 11066411
    Abstract: Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to A2A receptor. The R1, R2, R3, ring A, ring B, n, and m are as defined in the specification.
    Type: Grant
    Filed: April 8, 2018
    Date of Patent: July 20, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Yanxin Yu, Xinde Chen, Li Zhang, Zhaoguo Chen, Cheng Xie, Xiaofei Wang, Linghui Wu, Guoping Hu, Jian Li, Shuhui Chen
  • BORATE OF AZETIDINE DERIVATIVE
    Publication number: 20210163507
    Abstract: A borate compound of an azetidine derivative, relating in particular to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof or a geometric isomer thereof, as well as a use thereof in the preparation of a drug used for the treatment or prevention of multiple myeloma.
    Type: Application
    Filed: August 2, 2019
    Publication date: June 3, 2021
    Inventors: Jian Xiong, Cheng Xie, Xiongbin Xu, Kevin X Chen, Jian Li, Shuhui Chen, Aiming Zhang, Xiquan Zhang, Xin Tian
  • Azetidine derivative
    Patent number: 11014943
    Abstract: Disclosed in the present application are a compound represented by formula (I), or a pharmaceutically acceptable salt, a tautomer thereof, a stereoisomer thereof, or a geometrical isomer thereof, and uses thereof in the preparation of drugs for treating or preventing multiple myeloma.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: May 25, 2021
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP GO., LTD.
    Inventors: Jian Xiong, Cheng Xie, Kevin X Chen, Xiongbin Xu, Xuejin Zhang, Zhen Gong, Jian Li, Shuhui Chen, Aiming Zhang, Zhulian Jiang, Xiquan Zhang, Xin Tian
  • CRYSTAL FORM AND SALT TYPE OF TRIAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREOF
    Publication number: 20210094957
    Abstract: Disclosed in the present invention are a crystal form of a [1,2,4]triazolo[1,5-c]pyrimidine compound and a preparation method thereof. Further disclosed is a use of the crystal form in the preparation of a medicament for treating A2A receptor related diseases.
    Type: Application
    Filed: April 28, 2019
    Publication date: April 1, 2021
    Applicant: Medshine Discovery Inc.
    Inventors: Kevin X. Chen, Yanxin Yu, Xinde Chen, Li Zhang, Zhaoguo Chen, Cheng Xie
  • QUINAZOLINE DERIVATIVE AND USE THEREOF
    Publication number: 20210078958
    Abstract: The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as Pan-HER tyrosine kinase inhibitors.
    Type: Application
    Filed: December 19, 2018
    Publication date: March 18, 2021
    Applicant: Medshine Discovery Inc.
    Inventors: Kevin X. CHEN, XiaWei WEI, Li ZHANG, Yanxin YU, Kai ZHOU, Boyu HU, Zhaoguo CHEN, Huiyu ZHANG, Shuhui CHEN
  • ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVE
    Publication number: 20210032238
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 5, 2017
    Publication date: February 4, 2021
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Crystal Form of 3,4-Dihydrothieno[3,2-D]Pyrimidine Compound and Preparation Method Thereof
    Publication number: 20210024538
    Abstract: A crystal form A of a 3,4-dihydrothieno[3,2-d]pyrimidine compound (1), a preparation method therefor and an application thereof in the preparation of an anti-human cytomegalovirus (HCMV) drug.
    Type: Application
    Filed: January 29, 2019
    Publication date: January 28, 2021
    Inventors: Jian Xiong, Jingjing WANG, Boyu HU, Haizhong TAN, KEVIN X CHEN, jIAN li, Shuhui CHEN
  • CRYSTAL FORM AND SALT FORM OF PYRIDOIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR
    Publication number: 20200407354
    Abstract: Disclosed are a crystal form and a salt form of a pyrazolopridine compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.
    Type: Application
    Filed: March 5, 2019
    Publication date: December 31, 2020
    Inventors: Jian Xiong, Xiaoxin Chen, Jingjing Wang, Zhuowei Liu, Kevin X Chen, Chengwu Liu, Cheng Xie, Chaofeng Long, Peng Li, Jian Li, Shuhui Chen
  • Anti-HCMV virus compound
    Patent number: 10851112
    Abstract: Disclosed are a class of fused cyclic compounds against the HCMV virus, and use thereof in the preparation of a drugs for treating diseases associated with the HCMV virus. In particular, disclosed is the compound shown in formula (II) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: December 1, 2020
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Jian Xiong, Jingjing Wang, Wentao Wu, Haizhong Tan, Xuanjia Peng, Yang Zhang, Kevin X. Chen, Jian Li, Shuhui Chen
  • PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS
    Publication number: 20200339568
    Abstract: Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.
    Type: Application
    Filed: November 2, 2018
    Publication date: October 29, 2020
    Inventors: Kevin X CHEN, Zhaoguo CHEN, Li ZHANG, Yanxin YU, Kai ZHOU, Boyu HU, Xiaofei WANG, Guoping HU, Jian LI, Shuhui CHEN